Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
CardieX ( (AU:CDX) ) has issued an update.
Cardiex Limited reported a 10% increase in revenue for FY25, driven by the launch of its new product, Pulse. The company has implemented significant cost-reduction measures, resulting in a leaner expense structure. With increased net assets and support from C2 Ventures, Cardiex is well-positioned to pursue its FY26 growth strategy, benefiting from new revenue streams and strengthened liquidity.
More about CardieX
Cardiex is a company focused on advancing medical technology in vascular health. It offers a range of products including medical and home health devices and digital solutions for conditions like hypertension and cardiovascular disease, leveraging its SphygmoCor® vascular biomarker technology. Cardiex is listed on the Australian Stock Exchange (ASX: CDX).
Average Trading Volume: 447,789
Technical Sentiment Signal: Sell
Current Market Cap: A$16.5M
For detailed information about CDX stock, go to TipRanks’ Stock Analysis page.